PURPOSE: The renin-angiotensin system plays a crucial role in maintaining vascular homeostasis. Stimulation of angiotensin II type 1 receptors (AT1R) acts proangiogenically by increasing levels of vascular endothelial growth factor (VEGF). Consequently, cell culture experiments and animal studies have shown antiproliferative effects of AT1R blockers (ARB) and angiotensin I converting enzyme inhibitors (ACEI) in several malignancies. Until now, very limited clinical data for this antiangiogenic effect exists for combinations with antineoplastic chemotherapy. METHODS: A total of 287 patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy were retrospectively analysed regarding long-term medication with ACEI and ARB as well as histological type, stage, performance status, gender, age, dose-intensity of chemotherapy and survival. RESULTS: Patients receiving either ACEI or ARB had a 3.1 months longer median survival than non-recipients (11.7 vs. 8.6 months, HR 0.56, P = 0.03). This survival advantage could not be attributed to other established risk-factors or dose intensity of chemotherapy. CONCLUSIONS: Addition of ACEI or ARB to platinum-based first-line chemotherapy may contribute to prolonged survival in patients with advanced lung cancer.
PURPOSE: The renin-angiotensin system plays a crucial role in maintaining vascular homeostasis. Stimulation of angiotensin II type 1 receptors (AT1R) acts proangiogenically by increasing levels of vascular endothelial growth factor (VEGF). Consequently, cell culture experiments and animal studies have shown antiproliferative effects of AT1R blockers (ARB) and angiotensin I converting enzyme inhibitors (ACEI) in several malignancies. Until now, very limited clinical data for this antiangiogenic effect exists for combinations with antineoplastic chemotherapy. METHODS: A total of 287 patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy were retrospectively analysed regarding long-term medication with ACEI and ARB as well as histological type, stage, performance status, gender, age, dose-intensity of chemotherapy and survival. RESULTS:Patients receiving either ACEI or ARB had a 3.1 months longer median survival than non-recipients (11.7 vs. 8.6 months, HR 0.56, P = 0.03). This survival advantage could not be attributed to other established risk-factors or dose intensity of chemotherapy. CONCLUSIONS: Addition of ACEI or ARB to platinum-based first-line chemotherapy may contribute to prolonged survival in patients with advanced lung cancer.
Authors: O V Volpert; W F Ward; M W Lingen; L Chesler; D B Solt; M D Johnson; A Molteni; P J Polverini; N P Bouck Journal: J Clin Invest Date: 1996-08-01 Impact factor: 14.808
Authors: Christopher I Li; Kathleen E Malone; Noel S Weiss; Denise M Boudreau; Kara L Cushing-Haugen; Janet R Daling Journal: Cancer Date: 2003-10-01 Impact factor: 6.860
Authors: Ronald van der Knaap; Claire Siemes; Jan-Willem W Coebergh; Cornelia M van Duijn; Albert Hofman; Bruno H Ch Stricker Journal: Cancer Date: 2008-02-15 Impact factor: 6.860
Authors: Alex R Menter; Nikki M Carroll; Lori C Sakoda; Thomas Delate; Mark C Hornbrook; Rakesh K Jain; Lawrence H Kushi; Virginia P Quinn; Debra P Ritzwoller Journal: Clin Lung Cancer Date: 2016-08-20 Impact factor: 4.785
Authors: John D Martin; Dai Fukumura; Dan G Duda; Yves Boucher; Rakesh K Jain Journal: Cold Spring Harb Perspect Med Date: 2016-12-01 Impact factor: 6.915
Authors: Y Nakai; H Isayama; H Ijichi; T Sasaki; N Sasahira; K Hirano; H Kogure; K Kawakubo; H Yagioka; Y Yashima; S Mizuno; K Yamamoto; T Arizumi; O Togawa; S Matsubara; T Tsujino; K Tateishi; M Tada; M Omata; K Koike Journal: Br J Cancer Date: 2010-10-26 Impact factor: 7.640